Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Heterocyclic substituted piperazine compounds with CXCR3 antagonist activity

A compound and solvate technology, applied in the field of treating diseases and diseases involving CXCR3, can solve the problem of not showing such effects

Inactive Publication Date: 2009-08-26
SCHERING AG +1
View PDF15 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although IP-10 has been reported to induce chemotaxis of monocytes in vitro (Taub, D.D. et al., J. Exp. Med., 177:1809-1814 (1993), but the responsible receptor has not been identified), human Mig and I-TAC appear to be highly selective and show no such effects (Liao, F. et al., J. Exp. Med., 182:1301-1314 (1995); Cole, K.E. et al., J. Exp. Med., 187: 2009-2021 (1998))

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Heterocyclic substituted piperazine compounds with CXCR3 antagonist activity
  • Heterocyclic substituted piperazine compounds with CXCR3 antagonist activity
  • Heterocyclic substituted piperazine compounds with CXCR3 antagonist activity

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0401]

[0402] To a cold (-78°C) 1000ml round bottom flask containing 200ml methanol was added dropwise thionyl chloride (10ml, 140mmol) followed by 5-bromopyridinecarboxylic acid (15g, 75mmol). After stirring at -78°C for 10 minutes, the reaction was allowed to warm to room temperature and stirred for 16 hours. Excess thionyl chloride and methanol were removed in vacuo to give A2 (18 g, 95%) as a light brown solid. M+H=216

Embodiment 2

[0404]

[0405] A 250 ml round bottom flask was charged with A2 (4 g, 15.9 mmol), 1-Boc-2-S-ethylpiperazine A3 (prepared according to Kiley et al., Org. Prep. Proc. Int. 1990, 22, 761; 4.2 g, 18.6 mmol), tris(dibenzylideneacetone)dipalladium (340 mg, 0.37 mmol), rac-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (BINAP ) (495 mg, 0.74 mmol), cesium carbonate (12 g, 37.2 mmol) and toluene (80 ml). After heating the mixture at 100°C for 16 hours, fresh tris(dibenzylideneacetone)dipalladium (340 mg, 0.37 mmol) and BINAP (495 mg, 0.74 mmol) were added and heating continued for 3 days. The solvent was removed in vacuo and the residue was suspended in 100 ml of ethyl acetate. The mixture was extracted with water and brine, dried over sodium sulfate, and concentrated in vacuo. The residue was purified via silica gel flash chromatography (5% methanol / 95% DCM) to yield 5.3 g of partially purified material which was used directly in the next step. M+H=350

Embodiment 3

[0407]

[0408] Intermediate A4 (5.28 g, 15.1 mmol) was stirred with N-bromo-succinimide (5.4 g, 30.2 mmol) in 30 ml DMF at room temperature for 24 hours. The solvent was removed in vacuo and the residue was purified directly by flash chromatography on silica gel eluting with 50% ethyl acetate / 50% hexanes to afford A5 (1.22 g, 19% yield, M+H=428). The column was further eluted with 10% 7N ammonia in methanol / 90% DCM to afford A6 (1.28 g, 25%, M+H=328).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: Chemical formula should be inserted here as it appears on the abstract in paper form. or a pharmaceutically acceptable salt, solvate or ester thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non limiting example(s) include, psoriasis), autoimmune diseases (non limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non limiting example(s) include, allograft rejection, zenograft rejection), infectious diseases (e.g , tuberculoid leprosy), fixed drug eruptions, cutaneous delayed type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.

Description

Field of Invention [0001] The present invention relates to novel heterocyclic substituted piperazine compounds having CXCR3 antagonist activity; pharmaceutical compositions containing one or more such antagonists, one or more such compounds in combination with other compounds having chemokine activity class antagonists, one or more such antagonists in combination with known immunosuppressants, non-limiting examples of which include methotrexate, interferon, cyclosporine, FK-506 and FTY720; methods of making such antagonists and methods of modulating CXCR3 activity using such antagonists. The present invention also discloses methods of treating (non-limiting examples including palliative, curative and prophylactic therapy) diseases and disorders involving CXCR3 using such CXCR3 antagonists. Diseases and disorders involving CXCR3 include, but are not limited to, inflammatory diseases (psoriasis and inflammatory bowel disease), autoimmune diseases (multiple sclerosis, rheumatoid...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D401/12A61P37/06A61P29/00A61K31/496
CPCC07D401/14A61P17/06A61P19/02A61P25/00A61P25/28A61P29/00A61P31/04A61P31/12A61P35/00A61P37/02A61P37/06A61P43/00A61P9/10A61P3/10C07D401/12A61K31/496
Inventor S·B·罗森布伦J·A·科兹罗夫斯基N·-Y·施B·F·麦吉尼斯D·W·霍布斯
Owner SCHERING AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com